| Journal | Drug and alcohol dependence |
| Study Type | Clinical Study |
| Population | Human participants |
This study addresses a critical gap in understanding how cannabis policy affects treatment outcomes for pregnant women with cannabis use disorder. Given rising pregnancy cannabis use rates and evolving legalization landscape, clinicians need evidence on whether policy changes impact recovery success in this vulnerable population.
This retrospective cross-sectional analysis of 13,088 pregnant women admitted for cannabis use disorder treatment (2020-2022) found overall completion rates of 28.3%. Using TEDS-D data, researchers compared treatment outcomes across states with full legalization, medical-only programs, and prohibition policies. The study employed multivariable logistic regression to control for confounding variables and included subgroup analyses by treatment setting and referral source. Notable limitations include the observational design preventing causal inference and potential unmeasured confounders affecting both policy environments and treatment infrastructure.
“I find the 28% completion rate concerning regardless of legalization status – this suggests systemic treatment barriers for pregnant women that transcend cannabis policy. The study design limits our ability to determine whether legalization itself influences outcomes versus the broader healthcare infrastructure differences between states with varying policies.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- How common is treatment completion among pregnant women seeking help for cannabis use?
- Does cannabis legalization affect whether pregnant women complete treatment for cannabis use disorders?
- Should I be concerned about cannabis use during pregnancy?
- What factors influence treatment success for pregnant women with cannabis use disorders?
- How reliable is this evidence for making clinical decisions about pregnant patients who use cannabis?
FAQ
How common is treatment completion among pregnant women seeking help for cannabis use?
Based on this large national study of over 13,000 pregnant women, only 28.3% completed their substance use treatment for cannabis. This relatively low completion rate highlights significant challenges in engaging and retaining pregnant women in cannabis treatment programs.
Does cannabis legalization affect whether pregnant women complete treatment for cannabis use disorders?
This study examined treatment completion rates across states with different cannabis policies (fully legal, medical only, or illegal) from 2020-2022. The research suggests there may be associations between legalization status and treatment outcomes, though the specific relationships require careful interpretation given the complexity of policy environments.
Should I be concerned about cannabis use during pregnancy?
Cannabis is the most commonly used illicit substance during pregnancy in the United States, making it a significant clinical concern. The fact that thousands of pregnant women require formal treatment for cannabis use indicates that problematic use patterns can develop that may affect both maternal and fetal health.
What factors influence treatment success for pregnant women with cannabis use disorders?
This study analyzed various factors including treatment setting and referral source that may impact completion rates. The research suggests that treatment outcomes may vary based on how women enter treatment and the type of program they receive, indicating the importance of tailored approaches.
How reliable is this evidence for making clinical decisions about pregnant patients who use cannabis?
This study has “monitored relevance” classification, meaning it provides early-stage evidence that requires further research before definitive clinical action. While the large sample size from national treatment data is valuable, clinicians should consider this as contextual information alongside other evidence and individual patient factors.